Statera Biopharma Buy Hold or Sell Recommendation
| STABDelisted Stock | USD 0.04 0.0003 0.82% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Statera Biopharma is 'Not Rated'. Macroaxis provides Statera Biopharma buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding STAB positions.
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. In addition, we conduct extensive research on individual companies such as Statera and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Statera Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
Statera |
Execute Statera Biopharma Buy or Sell Advice
The Statera recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Statera Biopharma. Macroaxis does not own or have any residual interests in Statera Biopharma or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Statera Biopharma's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Not Rated
Statera Biopharma Trading Alerts and Improvement Suggestions
| Statera Biopharma is not yet fully synchronised with the market data | |
| Statera Biopharma has some characteristics of a very speculative penny stock | |
| Statera Biopharma has a very high chance of going through financial distress in the upcoming years | |
| Statera Biopharma currently holds 10.62 M in liabilities with Debt to Equity (D/E) ratio of 0.23, which may suggest the company is not taking enough advantage from borrowing. Statera Biopharma has a current ratio of 0.05, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Statera Biopharma until it has trouble settling it off, either with new capital or with free cash flow. So, Statera Biopharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Statera Biopharma sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Statera to invest in growth at high rates of return. When we think about Statera Biopharma's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 1.49 M. Net Loss for the year was (101.88 M) with profit before overhead, payroll, taxes, and interest of 998.72 K. | |
| Statera Biopharma currently holds about 506.1 K in cash with (28.19 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01. | |
| Roughly 16.0% of Statera Biopharma outstanding shares are owned by corporate insiders | |
| Latest headline from investing.com: Acrivon Therapeutics SWOT analysis oncology biotech stocks platform potential |
Statera Biopharma current analysts advice
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Statera analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Statera analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
The consensus estimates and target price estimation comprises individual analyst assessments, and may or may not mutch the Macroaxis buy or sell advice. It is determined by taking an average of all analyst recommendations and classifying them as Strong Buy, Buy, Hold, or Sell.
Statera Biopharma Returns Distribution Density
The distribution of Statera Biopharma's historical returns is an attempt to chart the uncertainty of Statera Biopharma's future price movements. The chart of the probability distribution of Statera Biopharma daily returns describes the distribution of returns around its average expected value. We use Statera Biopharma price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Statera Biopharma returns is essential to provide solid investment advice for Statera Biopharma.
| Mean Return | -1.64 | Value At Risk | -20 | Potential Upside | 16.13 | Standard Deviation | 12.04 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Statera Biopharma historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Statera Biopharma Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Statera . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Statera Biopharma Buy or Sell Advice
When is the right time to buy or sell Statera Biopharma? Buying financial instruments such as Statera Pink Sheet isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Statera Biopharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Most Shorted Equities Thematic Idea Now
Most Shorted Equities
Dynamically calculated list of top equities currently trending upward via a buy-out by investors. The Most Shorted Equities theme has 207 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Most Shorted Equities Theme or any other thematic opportunities.
| View All Next | Launch |
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Other Consideration for investing in Statera Pink Sheet
If you are still planning to invest in Statera Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Statera Biopharma's history and understand the potential risks before investing.
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites |